Publication Date
In 2025 | 0 |
Since 2024 | 0 |
Since 2021 (last 5 years) | 0 |
Since 2016 (last 10 years) | 1 |
Since 2006 (last 20 years) | 5 |
Descriptor
Incidence | 6 |
Patients | 6 |
Seizures | 6 |
Drug Therapy | 3 |
Epilepsy | 3 |
Risk | 3 |
Adults | 2 |
Attention Deficit… | 2 |
Mental Retardation | 2 |
Records (Forms) | 2 |
Symptoms (Individual… | 2 |
More ▼ |
Source
Developmental Medicine &… | 2 |
Journal of Intellectual… | 2 |
Autism: The International… | 1 |
Journal of Child Psychology… | 1 |
Author
Allen, Albert J. | 1 |
Arvio, M. | 1 |
Ball, Susan | 1 |
Banaschewski, Tobias | 1 |
Bangs, Mark E. | 1 |
Barnette, Debra | 1 |
Braun, Erika | 1 |
Buitelaar, Jan | 1 |
Ceulemans, Berten | 1 |
Clemson, L. | 1 |
Coghill, David | 1 |
More ▼ |
Publication Type
Journal Articles | 6 |
Reports - Research | 4 |
Information Analyses | 1 |
Numerical/Quantitative Data | 1 |
Reports - Descriptive | 1 |
Reports - Evaluative | 1 |
Education Level
Adult Education | 1 |
Elementary Secondary Education | 1 |
Audience
Practitioners | 1 |
Location
Ohio | 1 |
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Saqr, Youssra; Braun, Erika; Porter, Kyle; Barnette, Debra; Hanks, Christopher – Autism: The International Journal of Research and Practice, 2018
Little has been reported about how to improve health care access and delivery for adolescents and adults with autism spectrum disorder. To understand the contributions to the health disparities in the autism spectrum disorder population, we conducted two independent research approaches to learn about current medical needs. A retrospective chart…
Descriptors: Health Needs, Adolescents, Adults, Autism
Ceulemans, Berten – Developmental Medicine & Child Neurology, 2011
Dravet syndrome, or as it was called in the past "severe myoclonic epilepsy in infancy", is a drug-resistant epilepsy first described by Charlotte Dravet in 1978. Besides the well-known and well-described therapy resistance, Dravet syndrome dramatically impacts the development and behaviour of the affected children. As it is still not a curable…
Descriptors: Epilepsy, Seizures, Identification, Patients
Cortese, Samuele; Holtmann, Martin; Banaschewski, Tobias; Buitelaar, Jan; Coghill, David; Danckaerts, Marina; Dittmann, Ralf W.; Graham, John; Taylor, Eric; Sergeant, Joseph – Journal of Child Psychology and Psychiatry, 2013
Background: Medication is an important element of therapeutic strategies for ADHD. While medications for ADHD are generally well-tolerated, there are common, although less severe, as well as rare but severe adverse events AEs during treatment with ADHD drugs. The aim of this review is to provide
evidence- and expert-based guidance concerning the…
Descriptors: Attention Deficit Hyperactivity Disorder, Therapy, Drug Therapy, Incidence
Cox, C. R.; Clemson, L.; Stancliffe, R. J.; Durvasula, S.; Sherrington, C. – Journal of Intellectual Disability Research, 2010
Background: Falls among people with intellectual disability (ID) occur at a younger age than the general population and are a significant cause of injury and hospitalisation. There is very limited research investigating risk factors for falls among people with ID and none with people living outside of formal care arrangements, either independently…
Descriptors: Incidence, Mental Retardation, Injuries, Seizures
Wernicke, Joachim F.; Holdridge, Karen Chilcott; Jin, Ling; Edison, Timothy; Zhang, Shuyu; Bangs, Mark E.; Allen, Albert J.; Ball, Susan; Dunn, David – Developmental Medicine & Child Neurology, 2007
The comorbidity of seizures, epilepsy, and attention-deficit-hyperactivity disorder (ADHD) prompted the examination of whether atomoxetine use for ADHD is associated with an increased risk of seizures. Seizures and seizure-related symptoms were reviewed from two independent Eli Lilly and Company databases: the atomoxetine clinical trials database…
Descriptors: Epilepsy, Incidence, Seizures, Hyperactivity
Arvio, M.; Sillanpaa, M. – Journal of Intellectual Disability Research, 2005
To study the effectiveness of topiramate (TPM) in refractory epilepsy in patients who have intellectual disability (ID). A representative population sample of 57 patients with ID (age range 261, mean 32.8) was administered add-on TPM for drug-refractory epilepsy. Results Seizure freedom for at least for 6months was attained by 10 (17%), and…
Descriptors: Patients, Seizures, Epilepsy, Incidence